Literature DB >> 16763523

Osteonecrosis in patients infected with HIV: clinical epidemiology and natural history in a large case series from Spain.

Félix Gutiérrez1, Sergio Padilla, Mar Masiá, Juan Flores, Vicente Boix, Esperanza Merino, Josefa Galindo, Enrique Ortega, José López-Aldeguer, Carlos Galera.   

Abstract

BACKGROUND: There is a paucity of data on clinical epidemiology of osteonecrosis in HIV-infected patients. We aimed to describe patients' characteristics and natural history of this poorly known condition.
METHODS: All cases of symptomatic HIV-related osteonecrosis diagnosed from 1990 through 2003 in 19 Spanish clinics were reviewed. Functional status at the last visit was assessed with the validated Western Ontario and McMaster Universities Index questionnaire.
RESULTS: Of 54 patients analyzed, 29 (53.7%) had a single bone necrosis, and 25 (46.3%) had 2 or more sites involved. Progression of symptoms happened more often in patients with hip involvement (17/39 vs 0/8 patients; P = 0.019). Twenty patients (37%) required surgical intervention. Male sex and higher CD4 cell count were associated with surgery on multivariable analysis. Overall, at the end of the follow-up period, half of the patients had moderate to severe disability (Western Ontario and McMaster Universities Index score > or =60). During a follow-up period of 137 person-years, only 2 new episodes of osteonecrosis were observed (rate of recurrences, 1.5/100 person-years; 95% confidence interval, 0.4-5.1).
CONCLUSIONS: HIV-related osteonecrosis is associated with significant disability over time. Location of bone necrosis, sex, and CD4 cell count may influence the outcome. The risk for recurrences for patients who have experienced 1 episode is low.

Entities:  

Mesh:

Year:  2006        PMID: 16763523     DOI: 10.1097/01.qai.0000225012.53568.20

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  7 in total

1.  Avascular necrosis of the femoral head in HIV positive patients-an assessment of risk factors and early response to surgical treatment.

Authors:  L Chokotho; W J Harrison; N Lubega; N C Mkandawire
Journal:  Malawi Med J       Date:  2013-06       Impact factor: 0.875

2.  Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric case-control study.

Authors:  Elena Mazzotta; Adriana Agostinone; Raffaella Rosso; Antonio Di Biagio; Giuseppe Vittorio De Socio; Anna Cappelletti; Raffaele Zicolella; Ennio Polilli; Paolo Bonfanti; Luigi Di Matteo; Lamberto Manzoli; Giustino Parruti
Journal:  J Bone Miner Metab       Date:  2011-01-22       Impact factor: 2.626

3.  Operations about hip in human immunodeficiency virus-positive patients.

Authors:  Jeong Joon Yoo; Sae Hyung Chun; Young Sam Kwon; Kyung-Hoi Koo; Kang Sup Yoon; Hee Joong Kim
Journal:  Clin Orthop Surg       Date:  2010-02-04

4.  Osteonecrosis of the femoral head in patients with type 1 human immunodeficiency virus infection: clinical analysis and review.

Authors:  Jean-Cyr Yombi; Bernard Vandercam; Dunja Wilmes; Jean-Emile Dubuc; Anne Vincent; Pierre-Louis Docquier
Journal:  Clin Rheumatol       Date:  2009-03-10       Impact factor: 2.980

5.  Interferon β protects against avascular osteonecrosis through interleukin 6 inhibition and silent information regulator transcript-1 upregulation.

Authors:  Kyoung Min Kim; Sajeev Wagle; Young Jae Moon; Sung Il Wang; Byung-Hyun Park; Kyu Yun Jang; Jung Ryul Kim
Journal:  Oncotarget       Date:  2017-12-16

6.  Early Outcomes of Primary Total Hip Arthroplasty for Osteonecrosis of the Femoral Head in Patients with Human Immunodeficiency Virus in China.

Authors:  Chang-Song Zhao; Xin Li; Qiang Zhang; Sheng Sun; Ru-Gang Zhao; Juan Cai
Journal:  Chin Med J (Engl)       Date:  2015-08-05       Impact factor: 2.628

7.  Sequential Bilateral Rapid Destructive Inflammatory Coxarthrosis in a Patient with Human Immunodeficiency Virus.

Authors:  Hyeon Jun Kim; Sung Soo Kim; Su Jin Kim; Kyung Ho Lee
Journal:  Hip Pelvis       Date:  2018-06-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.